Integrum has announced a strategic organizational restructuring to accelerate the commercialization of OPRA Implant System and improve operational efficiency.

This restructuring supports the strategic shift announced by Integrum in February 2025 and reflects the company’s effort to align its resources with strategic priorities that will drive short-term revenue growth and profitability, it states.

“While the restructuring impacts valued colleagues, it is a natural consequence of our strategic shift announced in February and necessary to position Integrum for long-term success. By focusing our organization on commercialization activities, we can better serve our customers and accelerate the uptake of OPRA Implant System in the US and selected European markets. We are grateful for the contributions of all our team members and are committed to supporting those affected through this transition,” says Martin Hillsten, CEO of Integrum.

In February 2025, Integrum announced a cost reduction program expected to result in SEK 20 million in annual cost savings when fully implemented at the beginning of 2026. The current restructuring, together with new measures to reduce R&D activities and consultancy costs, is expected to further reduce the company’s cost base.